{"content":"<li class=\"n-box-item date-title\" data-end=\"1500436799\" data-start=\"1500350400\" data-txt=\"Monday, December 23, 2019\">Tuesday, July 18, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3279353\" data-ts=\"1500416611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279353-discoveryplus-9_4-scripps-networksplus-10_4-on-report-of-merger-discussion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery +9.4%, Scripps Networks +10.4% on report of merger discussion</a></h4><ul>     <li>Shares in Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) are <font color='green'>spiking 9.4%</font> after hours, and Scripps Networks Interactive (NYSE:<a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a>) <font color='green'>up 10.4%</font>, on a <i>Wall Street Journal</i> report that the <a href=\"https://twitter.com/DanaMattioli/status/887434976953868289\" target=\"_blank\">two are in talks to combine</a>.</li>   <li>The <i>WSJ</i> couldn't learn terms, though Discovery is worth about $15B and Scripps Networks $8.8B.</li>    <li>The two abandoned merger talks in 2014, in part because the family controlling Scripps wasn't ready to sell.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279353\" data-linked=\"Discovery +9.4%, Scripps Networks +10.4% on report of merger discussion\" data-tweet=\"$DISCA $DISCA $SNI - Discovery +9.4%, Scripps Networks +10.4% on report of merger discussion https://seekingalpha.com/news/3279353-discoveryplus-9_4-scripps-networksplus-10_4-on-report-of-merger-discussion?source=tweet\" data-url=\"https://seekingalpha.com/news/3279353-discoveryplus-9_4-scripps-networksplus-10_4-on-report-of-merger-discussion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279351\" data-ts=\"1500415877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279351-csx-nowminus-4-full-year-guidance-disappoints-analysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX now -4% as full-year guidance disappoints analysts</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> now <font color='red'>-4.1%</font> AH after an initial sharp gain following better than expected <a href=\"https://seekingalpha.com/news/3279299-csx-plus-3_5-percent-q2-earnings-beat-estimates-adds-500m-buyback\" target=\"_blank\">Q2 earnings</a>, as in-line guidance for the full year <a href=\"http://www.reuters.com/article/us-csx-results-idUSKBN1A32A9\" target=\"_blank\">fell short of analyst expectations</a>.</li>     <li>CSX said that adjusting for restructuring charges, it expects FY 2017 operating ratio in the \"mid-60s\" and earnings growth of ~25% from 2016, but analyst consensus projected full-year EPS of $2.31, 28% above the $1.81 the railroad reported for 2016.</li>     <li>CSX also said it was evaluating its strategy for distributing cash to shareholders, which at least one analyst interprets as a possible sign the company will pay out less cash to investors.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279351\" data-linked=\"CSX now -4% as full-year guidance disappoints analysts\" data-tweet=\"$CSX - CSX now -4% as full-year guidance disappoints analysts https://seekingalpha.com/news/3279351-csx-nowminus-4-full-year-guidance-disappoints-analysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3279351-csx-nowminus-4-full-year-guidance-disappoints-analysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279346\" data-ts=\"1500413859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279346-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+24.7%</font>. <a href='https://seekingalpha.com/symbol/EXPO' title='Exponent, Inc.'>EXPO</a> <font color='green'>+9.8%</font>. <a href='https://seekingalpha.com/symbol/UBIO' title='ProShares UltraPro NASDAQ Biotechnology ETF'>UBIO</a> <font color='green'>+4.1%</font>. <a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+2.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a> <font color='red'>-7.6%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='red'>-6.9%</font>. <a href='https://seekingalpha.com/symbol/MMYT' title='MakeMyTrip Limited'>MMYT</a> <font color='red'>-4.6%</font>. <a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/NVGS' title='Navigator Holdings Ltd.'>NVGS</a> <font color='red'>-3.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279346\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$VRTX $EXPO $UBIO - After Hours Gainers / Losers https://seekingalpha.com/news/3279346-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3279346-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279319\" data-ts=\"1500410219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279319-ibm-posts-21st-straight-revenue-decline-shares-down-1_5-aftermarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM posts 21st straight revenue decline; shares down 1.5% aftermarket</a></h4><ul><li>        International Business Machines (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) reports Q2 results that beat EPS estimates but missed on revenue. IBM has reported declining year-over-year revenue for 21 straight quarters.</li><li>               Cloud revenue, which gets divided up into different segments, totaled $15.1B for the trailing 12 months. Cloud revenue also falls under what IBM calls its strategic imperatives alongside mobile and security.&nbsp;</li><li>               Strategic imperatives revenue totaled $34.1B over the 12monhts,&nbsp;<font color='green'>up 11%</font>&nbsp;and representing 43% of overall revenues.&nbsp;</li><li>               Segment breakdown: Cognitive Solutions: $4.6B revenue (<font color='red'>-2.5%&nbsp;</font>Y/Y); Global Business Services: $4.1B (<font color='red'>-3.7%</font>); Technology Services &amp; Cloud Platforms: $8.4B (<font color='red'>-5.1%</font>); Systems: $1.7B (<font color='red'>-10.4%</font>); Global Financing: $415M (<font color='red'>-2.2%</font>). &nbsp;&nbsp;</li><li>Cash: IBM reported $3.5B in net cash from operating activities in the quarter and FCF of $2.6B. The company ended Q2 with $12.3B of cash on hand.</li><li>FY17 guidance: diluted EPS of at least $13.80 compared to $13.68 consensus.</li><li>        <a href=\"https://seekingalpha.com/pr/16889910-ibm-reports-2017-second-quarter-results\" target=\"_blank\">Press release</a> </li><li>                  IBM shares are&nbsp;<font color='red'>down 1.49%</font>&nbsp;aftermarket.&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3279290-international-business-machines-beats-0_23-misses-revenue\" target=\"_blank\">International Business Machines beats by $0.23, misses on revenue</a> (July 18)</li></ul> &nbsp;<br /><div class=\"tiny-share-widget\" data-id=\"3279319\" data-linked=\"IBM posts 21st straight revenue decline; shares down 1.5% aftermarket\" data-tweet=\"$IBM - IBM posts 21st straight revenue decline; shares down 1.5% aftermarket https://seekingalpha.com/news/3279319-ibm-posts-21st-straight-revenue-decline-shares-down-1_5-aftermarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279319-ibm-posts-21st-straight-revenue-decline-shares-down-1_5-aftermarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279318\" data-ts=\"1500410205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279318-united-continental-posts-q2-earnings-beat-guides-q3-prasm-flat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Continental posts Q2 earnings beat but guides Q3 PRASM flat</a></h4><ul>     <li>United Continental (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a>) <font color='red'>-3.1%</font>&nbsp;AH despite beating <a href=\"https://seekingalpha.com/news/3279300-united-continental-beats-0_12-beats-revenue\" target=\"_blank\">Q2 earnings</a> expectations, as it issues flat guidance for Q3 passenger revenue per available seat mile.</li>     <li>UAL says Q2 PRASM rose 2.1% and consolidated yield  gained 2% Y/Y, but it sees Q3 PRASM in the range of -1% to +1%, as well as 12.5%-14.5% pre-tax margin and capacity +4% Y/Y.</li>     <li>For the 12 months ended June 30, UAL's pre-tax income totaled $3.8B and return on invested capital was 17%.</li>     <li>UAL also says it delivered the top airline operation among major competitors, including the best completion, on-time arrival and departure performance, during Q2.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279318\" data-linked=\"United Continental posts Q2 earnings beat but guides Q3 PRASM flat\" data-tweet=\"$UAL - United Continental posts Q2 earnings beat but guides Q3 PRASM flat https://seekingalpha.com/news/3279318-united-continental-posts-q2-earnings-beat-guides-q3-prasm-flat?source=tweet\" data-url=\"https://seekingalpha.com/news/3279318-united-continental-posts-q2-earnings-beat-guides-q3-prasm-flat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279313\" data-ts=\"1500409701\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279313-vertex-pharmas-triple-combo-regimens-show-positive-effect-in-treatment-resistant-cf-patients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex Pharma&#39;s triple combo regimens show positive effect in treatment-resistant CF patients; shares ahead 24% after hours</a></h4><ul><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) is up&nbsp;<font color='green'>24%</font>&nbsp;after hours on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/16889863-vertex-announces-positive-phase-1-and-phase-2-data-three-different-triple-combination\" target=\"_blank\">announcement </a>of positive mid-stage results from three different triple combination regimens in cystic fibrosis &#40;CF&#41; patients who have one F508del mutation and one minimal function mutation, a severe and difficult-to-treat type of the disease.</li><li>Data from the Phase 2 trials showed mean absolute improvements in lung function of 9.7% and 12.0% as measured by percent predicted forced expiratory volume in one second (ppFEV1) in the regimens containing VX-152 and VX-440, respectively (in combination with tezacaftor and ivacaftor).</li><li>Phase 1 results showed a 9.6% improvement in ppFEV1 in patients treated with VX-659 + tezacaftor + ivacaftor.</li><li>In addition, preliminary data showed mean absolute improvements in ppFEV1 of 7.3% and 9.5% when VX-152 or VX-440 were added to tezacaftor and ivacaftor in CF patients with two copies of the F508del mutation.</li><li>No significant safety signals were observed.</li><li>Vertex has accelerated the development of Vx-445 and VX-659, both in Phase 2. Top-line data are expected in early 2018. Pivotal studies of at least one triple combo regimen will commence in H1 2018.</li><li>The company will host a conference call today at 5:00 pm ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279313\" data-linked=\"Vertex Pharma&#39;s triple combo regimens show positive effect in treatment-resistant CF patients; shares ahead 24% after hours\" data-tweet=\"$VRTX - Vertex Pharma&#39;s triple combo regimens show positive effect in treatment-resistant CF patients; shares ahead 24% after hours https://seekingalpha.com/news/3279313-vertex-pharmas-triple-combo-regimens-show-positive-effect-in-treatment-resistant-cf-patients?source=tweet\" data-url=\"https://seekingalpha.com/news/3279313-vertex-pharmas-triple-combo-regimens-show-positive-effect-in-treatment-resistant-cf-patients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279307\" data-ts=\"1500409467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279307-facebook-expanding-huge-new-mexico-data-center\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook expanding huge New Mexico data center</a></h4><ul>   <li>Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='green'>+2%</font>) will double its investment in New Mexico with <a href=\"https://finance.yahoo.com/m/50e17cb4-f60c-3dc8-9e7f-a7282a38c84b/ss_facebook-has-plans-to-expand.html\" target=\"_blank\">half-billion-dollar plans</a> that include a vast new data center that's getting bigger still.</li>    <li>The company broke ground on the first building in the center, to cover an area equal to 17 football fields, in October. That should go live in late 2018, and construction on the second building should run through 2020.</li>    <li>The property is under construction outside of Albuquerque near Los Lunas, which has agreed to give up property taxes for 30 years in exchange for a series of annual payments starting at $50,000, topping out under $500.000. The state has kicked in billion in bonds and other economic development funding.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279307\" data-linked=\"Facebook expanding huge New Mexico data center\" data-tweet=\"$FB - Facebook expanding huge New Mexico data center https://seekingalpha.com/news/3279307-facebook-expanding-huge-new-mexico-data-center?source=tweet\" data-url=\"https://seekingalpha.com/news/3279307-facebook-expanding-huge-new-mexico-data-center\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279299\" data-ts=\"1500408996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279299-csxplus-3_5-q2-earnings-beat-estimates-adds-500m-to-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX +3.5% as Q2 earnings beat estimates, adds $500M to buyback</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color='green'>+3.5%</font>&nbsp;AH after reporting better than expected <a href=\"https://seekingalpha.com/news/3279286-csx-beats-0_05\" target=\"_blank\">Q2 earnings</a> and revenues, with growth across nearly all markets that was driven primarily by coal-related gains, strength in core pricing and volume across the other markets, and increased fuel recovery.</li>     <li>CSX says it is on track to achieve record efficiency gains and a step-function improvement in its key  financial measures for the year given continued economic growth and stable coal markets.</li>     <li>CSX reaffirms guidance for FY 2017, seeing EPS +25%  to ~$2.26 vs. $2.30 analyst consensus, a full-year operating ratio in  the mid-60s and free cash flow before dividends of ~$1.5B.</li>     <li>Also, the CSX board authorizes an additional $500M for the current share repurchase program, which now totals $1.5B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279299\" data-linked=\"CSX +3.5% as Q2 earnings beat estimates, adds $500M to buyback\" data-tweet=\"$CSX - CSX +3.5% as Q2 earnings beat estimates, adds $500M to buyback https://seekingalpha.com/news/3279299-csxplus-3_5-q2-earnings-beat-estimates-adds-500m-to-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3279299-csxplus-3_5-q2-earnings-beat-estimates-adds-500m-to-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279293\" data-ts=\"1500408525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAA\" target=\"_blank\">BAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279293-banrominus-12_5-in-two-days-after-gold-production-fails-to-meet-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banro -12.5% in two days after gold production fails to meet guidance</a></h4><ul>     <li>Banro (NYSEMKT:<a href='https://seekingalpha.com/symbol/BAA' title='Banro Corporation'>BAA</a>) fell 9% in today's trading to cap a 12.5% plunge in two days after the miner's <a href=\"https://seekingalpha.com/pr/16888000-banro-announces-q2-2017-production-results-financing\" target=\"_blank\">Q2 gold production</a> fell short of expectations and left <a href=\"http://www.miningweekly.com/article/banros-lower-gold-output-leaves-year-end-guidance-out-of-reach-2017-07-18/rep_id:3650\" target=\"_blank\">year-end guidance out of reach</a>.</li>     <li>BAA&nbsp;says its Twangiza and Namoya operations produced a combined 38,739 oz. of gold during the quarter for YTD total production of nearly 85K oz.; the company says the lower than expected output, combined with instability in the Democratic Republic of Congo, means it will fall short of the full-year guidance of 210K-230K oz. of gold.</li>     <li>BAA&nbsp;says it continues to explore opportunities to raise additional financing and refinance existing obligations in light of its operational and working capital challenges.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279293\" data-linked=\"Banro -12.5% in two days after gold production fails to meet guidance\" data-tweet=\"$BAA - Banro -12.5% in two days after gold production fails to meet guidance https://seekingalpha.com/news/3279293-banrominus-12_5-in-two-days-after-gold-production-fails-to-meet-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3279293-banrominus-12_5-in-two-days-after-gold-production-fails-to-meet-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279286\" data-ts=\"1500408284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279286-csx-beats-0_05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX beats by $0.05</a></h4><ul><li>CSX (NYSE:<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a>): Q2 EPS of $0.64 <font color='green'>beats by $0.05</font>.</li><li>Revenue +8% Y/Y</li><li>Shares <font color='green'>+2.4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16889877-csx-corporation-announces-second-quarter-earnings-increase-share-repurchase-program\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279286\" data-linked=\"CSX beats by $0.05\" data-tweet=\"$CSX - CSX beats by $0.05 https://seekingalpha.com/news/3279286-csx-beats-0_05?source=tweet\" data-url=\"https://seekingalpha.com/news/3279286-csx-beats-0_05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279285\" data-ts=\"1500408257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBKR\" target=\"_blank\">IBKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279285-interactive-brokers-group-misses-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interactive Brokers Group misses by $0.04, beats on revenue</a></h4><ul><li>Interactive Brokers Group (IEX:<a href='https://seekingalpha.com/symbol/IBKR' title='Interactive Brokers Group, Inc.'>IBKR</a>): Q2 EPS of $0.32 <font color='red'>misses by $0.04</font>.</li><li>Revenue of $387M (+4.9% Y/Y) <font color='green'>beats by $15.06M</font>.</li><li>Shares <font color='green'>+1.1%</font>.</li><li><a href='https://seekingalpha.com/pr/16889872-interactive-brokers-group-announces-2q2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279285\" data-linked=\"Interactive Brokers Group misses by $0.04, beats on revenue\" data-tweet=\"$IBKR - Interactive Brokers Group misses by $0.04, beats on revenue https://seekingalpha.com/news/3279285-interactive-brokers-group-misses-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279285-interactive-brokers-group-misses-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279281\" data-ts=\"1500407876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERIC\" target=\"_blank\">ERIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279281-amid-continuing-losses-ericsson-to-speed-cost-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amid continuing losses, Ericsson to speed cost cuts</a></h4><ul>   <li>Hit by <a href=\"https://seekingalpha.com/news/3279084-lm-ericsson-telephone-company-reports-q2-results\" target=\"_blank\">continually declining sales</a>, Ericsson (<a href=\"http://seekingalpha.com/symbol/ERIC\" target=\"_blank\">ERIC</a> <font color='red'>-16.8%</font>) says it's going to <a href=\"https://www.wsj.com/articles/ericsson-steps-up-efficiency-plans-as-sales-decline-1500401734\" target=\"_blank\">step up cost-cutting plans</a> and warns that there's likely further down to go for earnings before a recovery.</li>    <li>&ldquo;In light of the current market outlook, we will accelerate our actions to ensure that we can meet our target of doubling the 2016 operating margin beyond 2018,&rdquo; says CEO Borje Ekholm.</li>    <li>Along with technology and portfolio shifts, the company will reduce capitalization of its product platform, software release development costs and hardware costs, which could hit second-half operating income by 2.9B kronor. More market adjustments could ding results for the coming 12 months by 3B-5B kronor.</li>    <li>Cost cuts won't hit research and development, the company says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279281\" data-linked=\"Amid continuing losses, Ericsson to speed cost cuts\" data-tweet=\"$ERIC - Amid continuing losses, Ericsson to speed cost cuts https://seekingalpha.com/news/3279281-amid-continuing-losses-ericsson-to-speed-cost-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3279281-amid-continuing-losses-ericsson-to-speed-cost-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279278\" data-ts=\"1500406449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPWR\" target=\"_blank\">SPWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279278-sunpower-oge-energy-to-build-solar-pv-power-plant-in-oklahoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunPower, OGE Energy to build solar PV power plant in Oklahoma</a></h4><ul>     <li>SunPower surges (<a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='green'>+6.8%</font>) after announcing it will team with OGE Energy (<a href='https://seekingalpha.com/symbol/OGE' title='OGE Energy Corp.'>OGE</a> <font color='green'>+0.5%</font>) to <a href=\"https://seekingalpha.com/pr/16888906-og-and-e-sunpower-announce-10-megawatt-solar-plant-oklahoma\" target=\"_blank\">build a 10 MW solar photovoltaic power plant</a> in Covington, Okla.</li>     <li>SPWR says it will design and build an Oasis power plant system - which has 50% fewer parts than conventional solar plants - at the site.</li>     <li>SunPower will provide operations and maintenance services once the plant begins commercial operation, which is expected in early 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279278\" data-linked=\"SunPower, OGE Energy to build solar PV power plant in Oklahoma\" data-tweet=\"$SPWR $SPWR $OGE - SunPower, OGE Energy to build solar PV power plant in Oklahoma https://seekingalpha.com/news/3279278-sunpower-oge-energy-to-build-solar-pv-power-plant-in-oklahoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3279278-sunpower-oge-energy-to-build-solar-pv-power-plant-in-oklahoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279274\" data-ts=\"1500405436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279274-maxim-bullish-on-abeona-sees-89-upside-on-prospects-of-lead-gene-therapy-candidate-ebminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2%</a></h4><ul><li>Maxim Group ups its fair value target for Abeona Therapeutics (<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+2.2%</font>) to $17 (89% upside) from $14 citing positive prospects for its lead gene therapy candidate, Orphan Drug-tagged EB-101, for the treatment of recessive dystrophic epidermolysis bullosa &#40;RDEB&#41;, an inherited disorder characterized by large painful blisters on the skin.</li><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT02579369?term=eb-101&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 study</a> is currently recruiting patients. According to ClinicalTrials.gov, the estimated primary completion date is year-end 2023.</li><li>Maxim says its valuation model is on the conservative side considering its assumption of $100K per procedure (one procedure/patient).</li><li>Source: Briefing.com</li></ul><div class=\"tiny-share-widget\" data-id=\"3279274\" data-linked=\"Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2%\" data-tweet=\"$ABEO - Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2% https://seekingalpha.com/news/3279274-maxim-bullish-on-abeona-sees-89-upside-on-prospects-of-lead-gene-therapy-candidate-ebminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3279274-maxim-bullish-on-abeona-sees-89-upside-on-prospects-of-lead-gene-therapy-candidate-ebminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279267\" data-ts=\"1500404269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHGE\" target=\"_blank\">BHGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279267-goldman-comes-out-bearish-on-baker-hughes-reinstates-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman comes out bearish on Baker Hughes, reinstates at Sell</a></h4><ul>     <li>Baker Hughes (<a href='https://seekingalpha.com/symbol/BHGE' title='Baker Hughes, a GE company'>BHGE</a> <font color='red'>-2.2%</font>) is resumed at Goldman Sachs with a <a href=\"http://www.barrons.com/articles/goldman-sachs-is-still-bearish-on-baker-hughes-1500389717\" target=\"_blank\">Sell rating</a> and $37 price target, citing a reduction in consensus estimates and downward revisions in guidance due to the weak environment for oil prices.</li>     <li>Goldman also sees BHGE's medium-term growth being hampered by low exposure to North  American completions, with good news from peers about completions possibly adding to the stock's underperformance.</li>     <li>The firm believes BHGE&rsquo;s business exposure is less attractive over the medium term than close peers Schlumberger (<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color='red'>-1%</font>) and Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color='red'>-0.5%</font>), which offer more exposure to U.S. pressure pumping.</li><li><a href=\"https://seekingalpha.com/news/3278997-two-analysts-launch-coverage-baker-hughes-one-buy-one-neutral\" target=\"_blank\">Yesterday</a>, Morgan&nbsp;Stanley issued an Overweight rating on BHGE while FBR rated the stock at Market Perform.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279267\" data-linked=\"Goldman comes out bearish on Baker Hughes, reinstates at Sell\" data-tweet=\"$BHGE $BKR $SLB - Goldman comes out bearish on Baker Hughes, reinstates at Sell https://seekingalpha.com/news/3279267-goldman-comes-out-bearish-on-baker-hughes-reinstates-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3279267-goldman-comes-out-bearish-on-baker-hughes-reinstates-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279266\" data-ts=\"1500403524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279266-technology-top-gainers-losers-of-2-45-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:45 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/DAIO' title='Data I/O Corporation'>DAIO</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ERIC' title='LM Ericsson Telephone Company'>ERIC</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279266\" data-linked=\"Technology - Top Gainers / Losers as of 2:45 pm\" data-tweet=\"$AKTS $DAIO $AAOI - Technology - Top Gainers / Losers as of 2:45 pm https://seekingalpha.com/news/3279266-technology-top-gainers-losers-of-2-45-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279266-technology-top-gainers-losers-of-2-45-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279260\" data-ts=\"1500400838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279260-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TANH' title='Tantech Holdings'>TANH</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ASM' title='Avino Silver & Gold Mines Ltd'>ASM</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/REI' title='Ring Energy, Inc.'>REI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279260\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$TANH $ASM $WMLP-OLD - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3279260-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279260-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279258\" data-ts=\"1500400250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTS\" target=\"_blank\">TTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279258-on-tile-shop-holdings-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Tile Shop Holdings&#39; Q2</a></h4><ul>     <li>Tile Shop Holdings (<a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a> <font color='red'>-23%</font>) reports comparable-same store sales growth of 0.5% in <a href=\"https://seekingalpha.com/pr/16888962-tile-shop-reports-second-quarter-2017-results\" target=\"_blank\">Q2</a>.</li>     <li>Gross margin remained flat at 69.7%.</li>     <li>SG&amp;A expense rate expanded 90 bps to 56.7%.</li>     <li>Adjusted EBITDA margin rate squeezed 110 bps to 21.4%.</li>     <li>Store count +13 Y/Y to 130.</li>     <li><b>FY2017 Guidance</b>: Net sales: $350M to $365M; Comparable-store sales growth:&nbsp;low to mid single digits; Gross margin rate: ~70%; D&amp;A: ~$26M; Tax rate: 38%; Diluted EPS: $0.48 to $0.55; Adjusted EPS: $0.49 to $0.56; Adjusted EBITDA: $72M to $78M; Fully diluted shares: ~52M; Capex: ~$35M; New stores: ~15.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279258\" data-linked=\"More on Tile Shop Holdings&#39; Q2\" data-tweet=\"$TTS $TTSH - More on Tile Shop Holdings&#39; Q2 https://seekingalpha.com/news/3279258-on-tile-shop-holdings-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279258-on-tile-shop-holdings-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279364\" data-ts=\"1500399557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCJ\" target=\"_blank\">CCJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279364-uranium-miners-cameco-denison-downgraded-credit-suisse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uranium miners Cameco, Denison downgraded at Credit Suisse</a></h4><ul>     <li>Uranium producers Cameco (<a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='red'>-3.5%</font>) and Denison Mines (<a href='https://seekingalpha.com/symbol/DNN' title='Denison Mines Corp'>DNN</a> <font color='red'>-1.4%</font>) are sharply lower after Credit Suisse <a href=\"http://thefly.com/thestreet/realmoney/index.php/CCJid2579481/CCJ-Cameco-downgraded-to-Underperform-at-Credit-Suisse\" target=\"_blank\">downgrades</a> both stocks to Underperform from Neutral.</li><li>Credit Suisse says its cataloguing of nuclear power plants drives its  forecast for uranium demand below current industry expectations, which will result in a prolonged period of sub-$40/lb uranium prices, based on the 90th percentile of the cost curve, from a prior forecast for $60/lb. based on an incentive price.</li><li>The firm believes the value of  the companies' development portfolio is highly dependent on the  longer-term uranium price outlook and the need for new uranium mine  supply.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279364\" data-linked=\"Uranium miners Cameco, Denison downgraded at Credit Suisse\" data-tweet=\"$CCJ $CCJ $DNN - Uranium miners Cameco, Denison downgraded at Credit Suisse https://seekingalpha.com/news/3279364-uranium-miners-cameco-denison-downgraded-credit-suisse?source=tweet\" data-url=\"https://seekingalpha.com/news/3279364-uranium-miners-cameco-denison-downgraded-credit-suisse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279257\" data-ts=\"1500398701\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279257-financials-top-5-gainers-losers-of-1-25-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:25 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VNO' title='Vornado Realty Trust'>VNO</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='red'>-17%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279257\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:25 PM\" data-tweet=\"$YRD $VNO $MLP - Financials - Top 5 Gainers / Losers as of 1:25 PM https://seekingalpha.com/news/3279257-financials-top-5-gainers-losers-of-1-25-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279257-financials-top-5-gainers-losers-of-1-25-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279255\" data-ts=\"1500398171\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGNT\" target=\"_blank\">CGNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279255-cogentix-inks-deal-promepla-to-launch-endo-urology-products-in-u-s-shares-ahead-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cogentix inks deal with Promepla to launch endo-urology products in U.S.; shares ahead 10%</a></h4><ul><li>Cogentix Medical (<a href='https://seekingalpha.com/symbol/CGNT' title='Cogentix Medical, Inc.'>CGNT</a> <font color='green'>+10.1%</font>) enters into an exclusive license <a href=\"https://seekingalpha.com/pr/16888787-cogentix-medical-signs-agreement-launch-endo-urology-product-line-us-launch-increase-urology\" target=\"_blank\">agreement </a>with Monaco-based Promepla with the intent of launching a line of endo-urology products in the U.S. The portfolio includes ureteral access sheaths, gravity irrigation lines and nitinol guide wires.</li><li>Preparations for the launch are underway. Cogentix says the products will generate more than $2.5M in sales next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279255\" data-linked=\"Cogentix inks deal with Promepla to launch endo-urology products in U.S.; shares ahead 10%\" data-tweet=\"$CGNT - Cogentix inks deal with Promepla to launch endo-urology products in U.S.; shares ahead 10% https://seekingalpha.com/news/3279255-cogentix-inks-deal-promepla-to-launch-endo-urology-products-in-u-s-shares-ahead-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3279255-cogentix-inks-deal-promepla-to-launch-endo-urology-products-in-u-s-shares-ahead-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279253\" data-ts=\"1500397626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTP\" target=\"_blank\">MTP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279253-midatech-pharma-sees-37-bump-in-h1-sales-to-5_2m-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midatech Pharma sees 37% bump in H1 sales to \u20a45.2M; shares ahead 2%</a></h4><ul><li>On a preliminary basis, Midatech Pharma (<a href='https://seekingalpha.com/symbol/MTP' title='Midatech Pharma PLC'>MTP</a> <font color='green'>+2.3%</font>) expects total H1 revenues of \u20a45.2M, a 37% increase yoy. It says that it remains on-track to meet expectations for the year.</li><li>CEO Dr&nbsp;Jim Phillips says, \"I am pleased to report that Midatech's U.S. commercial business has continued to grow strongly in 2017. &nbsp;Looking into the second half of the year and beyond, the group remains focused on three lead research and development programmes, the first of which, Q-Octreotide, remains on-track to release important bioequivalence data in Q4 of the current year. We anticipate similar revenue growth for H2 2017 compared to the first half of the year and being able to deliver full-year revenues in line with current market expectations.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3279253\" data-linked=\"Midatech Pharma sees 37% bump in H1 sales to \u20a45.2M; shares ahead 2%\" data-tweet=\"$MTP - Midatech Pharma sees 37% bump in H1 sales to \u20a45.2M; shares ahead 2% https://seekingalpha.com/news/3279253-midatech-pharma-sees-37-bump-in-h1-sales-to-5_2m-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279253-midatech-pharma-sees-37-bump-in-h1-sales-to-5_2m-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279248\" data-ts=\"1500396727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279248-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/EDUC' title='Educational Development Corporation'>EDUC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/TANH' title='Tantech Holdings'>TANH</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/JCTCF' title='Jewett-Cameron Trading Company'>JCTCF</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SKIS' title='Peak Resorts'>SKIS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color='red'>-54%</font>. <a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ERIC' title='LM Ericsson Telephone Company'>ERIC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SNGX' title='Soligenix, Inc.'>SNGX</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy'>PIXY</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>&nbsp;<font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279248\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$NVAX $MBRX $EDUC - Midday Gainers / Losers https://seekingalpha.com/news/3279248-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3279248-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279246\" data-ts=\"1500396168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279246-infineraplus-2_5-after-craig-hallum-starts-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinera +2.5% after Craig-Hallum starts at Buy</a></h4><ul>    <li>Infinera (NASDAQ:<a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>) is <font color='green'>up 2.5%</font> today after a launch at Buy by Craig-Hallum.</li>    <li>The firm has a price target of $15, implying 29% upside from today's price.</li>    <li>Yesterday, Deutsche Bank reiterated its Buy rating on shares and bumped its price target, to $12.50 from $12.</li>    <li>Infinera is set to report earnings Aug. 3 after the closing bell; it's expected to post EPS of -$0.16 on revenues of $181.2M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279246\" data-linked=\"Infinera +2.5% after Craig-Hallum starts at Buy\" data-tweet=\"$INFN - Infinera +2.5% after Craig-Hallum starts at Buy https://seekingalpha.com/news/3279246-infineraplus-2_5-after-craig-hallum-starts-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3279246-infineraplus-2_5-after-craig-hallum-starts-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279243\" data-ts=\"1500396040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNRX\" target=\"_blank\">VNRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279243-volitionrx-unit-to-participate-in-large-scale-study-to-validate-biomarkers-for-crc-screening\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VolitionRx unit to participate in large-scale study to validate biomarkers for CRC screening test; shares ahead 3%</a></h4><ul><li>VolitionRx (<a href='https://seekingalpha.com/symbol/VNRX' title='VolitionRX Ltd'>VNRX</a> <font color='green'>+3.4%</font>) subsidiary Volition America inks an <a href=\"https://seekingalpha.com/pr/16888734-volition-america-inc-announces-colorectal-cancer-screening-trial-containing-approximately\" target=\"_blank\">agreement </a>with the Great Lakes New England Clinical Validation Center to participate in a large (13,500 samples) study in asymptomatic people aimed at validating a panel of biomarkers, including Volition's Nu.Q Colorectal Cancer Screening Test, to support U.S. regulatory approval.</li><li>Collecting the samples will take as long as three years. Volition America will contribute up to $3M to the effort, paid over a three-year period.</li><li>The Great Lakes organization is funded by the U.S. National Cancer Institute's Early Detection Research Network.</li><li>The company will host a conference call on Thursday, July 20, at 8:30 am ET to discuss the study and to provide a business update.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279243\" data-linked=\"VolitionRx unit to participate in large-scale study to validate biomarkers for CRC screening test; shares ahead 3%\" data-tweet=\"$VNRX - VolitionRx unit to participate in large-scale study to validate biomarkers for CRC screening test; shares ahead 3% https://seekingalpha.com/news/3279243-volitionrx-unit-to-participate-in-large-scale-study-to-validate-biomarkers-for-crc-screening?source=tweet\" data-url=\"https://seekingalpha.com/news/3279243-volitionrx-unit-to-participate-in-large-scale-study-to-validate-biomarkers-for-crc-screening\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279241\" data-ts=\"1500395370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPGP\" target=\"_blank\">IPGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279241-ipg-photonicsminus-2_8-canaccord-cuts-to-hold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IPG Photonics -2.8% as Canaccord cuts to Hold</a></h4><ul>   <li>IPG Photonics (NASDAQ:<a href='https://seekingalpha.com/symbol/IPGP' title='IPG Photonics Corporation'>IPGP</a>) is <font color='red'>off 2.8%</font> as Canaccord Genuity downgrades the shares to Hold, citing slowing demand in machine tool sales.</li>    <li>Taiwanese demand for machine tools flattened out in May and fell 3% in June in its first drop since last summer, notes Bobby Burleson. He sees tough comps for QCW lasers next year as well. (h/t Bloomberg)</li>    <li>A month ago, Canaccord had <a href=\"https://seekingalpha.com/news/3274044-canaccord-raises-ipg-photonics-price-target\" target=\"_blank\">boosted its price target</a> to $152 and keeps it there with the downgrade; that now represents 1.7% upside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279241\" data-linked=\"IPG Photonics -2.8% as Canaccord cuts to Hold\" data-tweet=\"$IPGP - IPG Photonics -2.8% as Canaccord cuts to Hold https://seekingalpha.com/news/3279241-ipg-photonicsminus-2_8-canaccord-cuts-to-hold?source=tweet\" data-url=\"https://seekingalpha.com/news/3279241-ipg-photonicsminus-2_8-canaccord-cuts-to-hold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279240\" data-ts=\"1500395217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279240-new-finance-chief-insys-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New finance chief at Insys; shares up 2%</a></h4><ul><li>Insys Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+1.5%</font>) <a href=\"https://seekingalpha.com/pr/16888748-insys-therapeutics-inc-appoints-andrew-g-long-chief-financial-officer\" target=\"_blank\">appoints </a>Andrew Long as Chief Financial Officer effective August 7, replacing Darryl Baker who will depart to pursue other opportunities. Most recently, he served as SVP of Global Finance at Patheon.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267694-new-finance-chief-hired-insys\" target=\"_blank\">New finance chief to be hired at Insys</a> (May 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279240\" data-linked=\"New finance chief at Insys; shares up 2%\" data-tweet=\"$INSY $INSYQ - New finance chief at Insys; shares up 2% https://seekingalpha.com/news/3279240-new-finance-chief-insys-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279240-new-finance-chief-insys-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279239\" data-ts=\"1500394786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QURE\" target=\"_blank\">QURE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279239-uniqure-nabs-u-s-patent-covering-aav-technology-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">uniQure nabs U.S. patent covering AAV technology; shares ahead 1%</a></h4><ul><li>The USPTO <a href=\"https://seekingalpha.com/pr/16888802-uniqure-expands-intellectual-property-portfolio-newly-issued-patent-providing-broad\" target=\"_blank\">grants </a>a patent (#9,708,627) to uniQure N.V. (<a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a> <font color='green'>+1.2%</font>) covering a component of insect cell-based AAV manufacturing technology. Specifically, the '627 patent covers the expression of Rep78 and Rep52 proteins from a Rep78 nucleic acid sequence in insect cells.</li><li>The company says '627 significantly expands its IP portfolio related to large-scale, highly reproducible manufacturing of AAV in insect cells because the technology is widely applied in the space.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279239\" data-linked=\"uniQure nabs U.S. patent covering AAV technology; shares ahead 1%\" data-tweet=\"$QURE - uniQure nabs U.S. patent covering AAV technology; shares ahead 1% https://seekingalpha.com/news/3279239-uniqure-nabs-u-s-patent-covering-aav-technology-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3279239-uniqure-nabs-u-s-patent-covering-aav-technology-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279236\" data-ts=\"1500394130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279236-schwab-sinks-1_5-following-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schwab sinks 1.5% following Q2 results</a></h4><ul><li>Schwab (<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a> <font color='red'>-1.5%</font>) revenues topped expectations and earnings were inline, but investors are selling the news.</li><li>Still a bull on the stock, Jefferies' Dan Fannon<a href=\"http://www.barrons.com/articles/schwab-close-but-no-cigar-1500393125\" target=\"_blank\"> takes note of</a> revenue per trade as the impact of the mid-February commission cuts filter through to a full quarter - it fell to $7.96 in Q2 from $9.84 in Q1.</li><li>Net new accounts in Q2 of 357K vs. 362K in Q1. Net new assets in Q2 of $63.9B were a multi-year high.</li><li>Fannon: \"We remain watchful of how the aforementioned commission price cuts might impact assets in motion as well as account growth.\"</li><li>Fannon's $49 price target suggests&nbsp;<font color='green'>16% upside</font>&nbsp;from the current level.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279168-charles-schwab-eps-line-beats-revenue\" target=\"_blank\">Charles Schwab EPS in-line, beats on revenue</a> (July 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279236\" data-linked=\"Schwab sinks 1.5% following Q2 results\" data-tweet=\"$SCHW - Schwab sinks 1.5% following Q2 results https://seekingalpha.com/news/3279236-schwab-sinks-1_5-following-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3279236-schwab-sinks-1_5-following-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279234\" data-ts=\"1500393698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279234-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CAW' title='CCA Industries Inc'>CAW</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a> <font color='red'>-9%</font>. LTEA <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279234\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ANFI $CAW $RIBT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3279234-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279234-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279231\" data-ts=\"1500393531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRAN\" target=\"_blank\">PRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279231-prana-bio-teams-up-takeda-to-study-potential-of-pbt434-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prana Bio teams up with Takeda to study potential of PBT434; shares ahead 6%</a></h4><ul><li>Prana Biotech (<a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a> <font color='green'>+5.9%</font>) enters into a research <a href=\"https://seekingalpha.com/pr/16889280-prana-commences-research-collaboration-takeda-treatment-parkinsons-disease-gastrointestinal\" target=\"_blank\">collaboration </a>with Takeda Pharmaceutical (<a href='https://seekingalpha.com/symbol/TKPHF' title='Takeda Pharmaceutical Co., Ltd.'>OTCPK:TKPHF</a>) aimed at investigating the ability of PBT434 to mitigate gastrointestinal dysfunction (constipation, lowered colon motility, inflammation) in mouse models.</li><li>PBT434 belongs to a class of molecules called quinazolinones which block the accumulation and aggregation of a protein called <a href=\"https://www.michaeljfox.org/understanding-parkinsons/living-with-pd/topic.php?alpha-synuclein\" target=\"_blank\">alpha-synuclein</a>, which is associated with Parkinson's disease and Lewy body dementia.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279231\" data-linked=\"Prana Bio teams up with Takeda to study potential of PBT434; shares ahead 6%\" data-tweet=\"$PRAN $ATHE $TKPHF - Prana Bio teams up with Takeda to study potential of PBT434; shares ahead 6% https://seekingalpha.com/news/3279231-prana-bio-teams-up-takeda-to-study-potential-of-pbt434-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3279231-prana-bio-teams-up-takeda-to-study-potential-of-pbt434-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279230\" data-ts=\"1500393225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279230-crude-oil-rises-report-says-saudis-will-cut-exports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude oil rises as report says Saudis will further cut exports</a></h4><ul>     <li><a href=\"http://www.marketwatch.com/story/oil-prices-edge-up-recovering-a-little-from-prior-days-slump-2017-07-18\" target=\"_blank\">Crude oil rallies</a> as much as 2% before pulling back, following a <em>Financial Times</em> report that Saudi Arabia is considering cutting crude exports by 1M bbl/day; WTI now <font color='green'>+0.6%</font> at $46.29/bbl.</li><li>The report cites a recent note to clients from Bill Farren-Price, a consultant at  Petroleum Policy Intelligence, who said the Saudi move would offset  the rise in Libyan and Nigerian supplies.</li><li>&ldquo;This is what OPEC has resorted to, export cuts in order to jawbone the  market higher,&rdquo; says iiTRADER chief market strategist Bill Baruch. &ldquo;We believe that OPEC members are getting restless and instead of this  news showing how stable a deal they have, its shows the holes.&rdquo;</li><li>Also, Ecuador - one of the  smaller OPEC producers - said it would <a href=\"https://seekingalpha.com/news/3279111-ecuador-breaks-ranks-opec\" target=\"_blank\">not be able to  hold its commitment</a> to lower output by 26K bbl/day.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279230\" data-linked=\"Crude oil rises as report says Saudis will further cut exports\" data-tweet=\"$USO $OIL $UWT - Crude oil rises as report says Saudis will further cut exports https://seekingalpha.com/news/3279230-crude-oil-rises-report-says-saudis-will-cut-exports?source=tweet\" data-url=\"https://seekingalpha.com/news/3279230-crude-oil-rises-report-says-saudis-will-cut-exports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279226\" data-ts=\"1500392378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLR\" target=\"_blank\">FLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279226-fluor-promotes-stanski-to-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fluor promotes Stanski to CFO</a></h4><ul>     <li>Fluor (<a href='https://seekingalpha.com/symbol/FLR' title='Fluor Corporation'>FLR</a> <font color='red'>-2.4%</font>) appoints Bruce Stanski as its <a href=\"https://seekingalpha.com/pr/16888753-fluor-selects-bruce-stanski-new-chief-financial-officer\" target=\"_blank\">new CFO</a> effective Aug. 4, replacing Biggs Porter, who previously had announced his retirement.</li>     <li>Stanski has served as the president of FLR's Government Group since 2009; previously he had been President of Government and Infrastructure of KBR during 2007-09.</li>     <li>Thomas D&rsquo;Agostino will replace Stanski as head of FLR&rsquo;s Government Group.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279226\" data-linked=\"Fluor promotes Stanski to CFO\" data-tweet=\"$FLR - Fluor promotes Stanski to CFO https://seekingalpha.com/news/3279226-fluor-promotes-stanski-to-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3279226-fluor-promotes-stanski-to-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279221\" data-ts=\"1500390095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279221-bofa-and-goldman-lead-banks-lower-after-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA and Goldman lead banks lower after results</a></h4><ul><li>UBS's Saul Martinez describes Bank of America's (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-1.5%</font>) results as a low-quality beat in a messy quarter with multiple non-core items. Net interest income underperformed (NIM actually fell during quarter). He keeps his Neutral rating and $26 price target.</li><li>Susan Roth Katzke from Credit Suisse sticks with an Outperform rating, and calls the results net positive, noting materially improved operating efficiency.</li><li>On Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-2.2%</font>), Barclays' Jason Goldberg says a lower tax rate, and higher investing and lending revenues made up for the plunge in trading revenues (which failed to hit materially reduced expectations). He remains neutral on the stock.</li><li>A more bullish Glenn Schorr from Evercore ISI says the weak FICC result is \"a shame\" given how well the rest of the bank's operations went.</li><li>Also lower after beating estimates is Comerica (<a href='https://seekingalpha.com/symbol/CMA' title='Comerica Inc.'>CMA</a> <font color='red'>-2.3%</font>).</li><li><a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a><font color='red'> -0.5%</font>, <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>&nbsp;<font color='red'>-0.8%</font>, <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>&nbsp;<font color='red'>-0.9%</font></li><li>Source: Felice Maranz at Bloomberg.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279221\" data-linked=\"BofA and Goldman lead banks lower after results\" data-tweet=\"$BAC $BAC $GS - BofA and Goldman lead banks lower after results https://seekingalpha.com/news/3279221-bofa-and-goldman-lead-banks-lower-after-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3279221-bofa-and-goldman-lead-banks-lower-after-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279198\" data-ts=\"1500390040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279198-healthcare-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/DYNT' title='Dynatronics Corporation'>DYNT</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color='red'>-48%</font>. <a href='https://seekingalpha.com/symbol/SNGX' title='Soligenix, Inc.'>SNGX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279198\" data-linked=\"Healthcare Gainers / Losers as of 11:00 am\" data-tweet=\"$MBRX $NVAX $TTOO - Healthcare Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3279198-healthcare-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3279198-healthcare-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279218\" data-ts=\"1500389911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTOO\" target=\"_blank\">TTOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279218-t2-bios-bacteria-panel-ce-markd-shares-ahead-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T2 Bio&#39;s bacteria panel CE Mark&#39;d; shares ahead 14%</a></h4><ul><li>Thinly traded nano cap T2 Biosystems (<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color='green'>+13.5%</font>) heads north on almost a 4x surge in volume after it <a href=\"https://seekingalpha.com/pr/16888999-t2-biosystems-receives-ce-mark-t2bacteria-panel-enabling-commercialization-europe\" target=\"_blank\">announced </a>CE Mark certification for its T2Bacteria Panel performed on its T2Dx instrument. The panel detects specific species of bacteria in whole blood samples in as little as 3.5 hours, without the need for a blood culture.</li><li>The panel is available in the U.S. on a research use-only basis but 510(k) clearance is expected by year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279218\" data-linked=\"T2 Bio&#39;s bacteria panel CE Mark&#39;d; shares ahead 14%\" data-tweet=\"$TTOO - T2 Bio&#39;s bacteria panel CE Mark&#39;d; shares ahead 14% https://seekingalpha.com/news/3279218-t2-bios-bacteria-panel-ce-markd-shares-ahead-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3279218-t2-bios-bacteria-panel-ce-markd-shares-ahead-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279217\" data-ts=\"1500389529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279217-chipotle-shuts-restaurant-after-customers-become-ill-sharesminus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle shuts restaurant after customers become ill; shares -4%</a></h4><ul>     <li>Chipotle Mexican Grill (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='red'>-4.6%</font>) plunges following a report that the company shut down a restaurant in Virginia after <a href=\"http://www.businessinsider.com/chipotle-closes-restaurant-where-customers-got-sick-2017-7\" target=\"_blank\">customers said they fell severely ill</a>.</li>     <li>Customers reportedly complained of vomiting, diarrhea, severe stomach pain, dehydration and nausea after eating at the restaurant; one person reported two hospitalizations due to the illnesses.</li>     <li>\"The reported symptoms are consistent with norovirus. Norovirus does not come from our food supply, and it is safe to eat at Chipotle,\" says CMG's director of food safety.</li>     <li>Before the report, Maxim Group <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9788022/test-queso-get-upgrade-analyst-turns-bullish-on-chipotle\" target=\"_blank\">upgraded CMG to Buy</a> from Hold with a $470 price target, raised from $440, citing the introduction of Mexican cheese dip queso - now in testing - will be an important catalyst for the stock in 2018.</li>     <li>Maxim thinks the recent pullback in shares, along with the potential for upside from queso, provide an opportunity for investors to participate in CMG's  recovery.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279217\" data-linked=\"Chipotle shuts restaurant after customers become ill; shares -4%\" data-tweet=\"$CMG - Chipotle shuts restaurant after customers become ill; shares -4% https://seekingalpha.com/news/3279217-chipotle-shuts-restaurant-after-customers-become-ill-sharesminus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3279217-chipotle-shuts-restaurant-after-customers-become-ill-sharesminus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>89&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279214\" data-ts=\"1500388600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279214-capricors-dmd-candidate-nabs-rare-pediatric-disease-designation-from-fda-shares-ahead-115\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capricor&#39;s DMD candidate nabs Rare Pediatric Disease Designation from FDA; shares ahead 115%</a></h4><ul><li>Thinly traded nano cap Capricor Therapeutics (<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+114.7%</font>) rockets up on a whopping 60x surge in volume in response to the <a href=\"https://seekingalpha.com/pr/16888997-capricor-receives-rare-pediatric-disease-designation-fda-capminus-1002-patients-duchenne\" target=\"_blank\">news </a>that the FDA has granted Rare Pediatric Disease Designation to lead product candidate CAP-1002 for the treatment of Duchenne muscular dystrophy &#40;DMD&#41;.</li><li>The main benefit of the designation is the awarding of a Priority Review Voucher if the product is approved. The voucher can be used for accelerated review for a another product candidate or it can be sold to a third party.</li><li>A registration study is on tap for H2. 12-month data from the Phase 1/2 HOPE study should be available in Q4.</li><li><a href=\"http://capricor.com/product-pipeline/cap-1002/\" target=\"_blank\">CAP-1002</a>&nbsp;is an investigational allogeneic, off-the-shelf cardiac cell therapy derived from donor heart tissue and infused directly into the patients coronary artery via a catheter.&nbsp;It is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack).</li></ul><div class=\"tiny-share-widget\" data-id=\"3279214\" data-linked=\"Capricor&#39;s DMD candidate nabs Rare Pediatric Disease Designation from FDA; shares ahead 115%\" data-tweet=\"$CAPR - Capricor&#39;s DMD candidate nabs Rare Pediatric Disease Designation from FDA; shares ahead 115% https://seekingalpha.com/news/3279214-capricors-dmd-candidate-nabs-rare-pediatric-disease-designation-from-fda-shares-ahead-115?source=tweet\" data-url=\"https://seekingalpha.com/news/3279214-capricors-dmd-candidate-nabs-rare-pediatric-disease-designation-from-fda-shares-ahead-115\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279211\" data-ts=\"1500387646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMUC\" target=\"_blank\">IMUC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279211-immunocellular-prices-equity-offering-shares-down-48\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunocellular prices equity offering; shares down 48%</a></h4><ul><li>ImmunoCellular Therapeutics (<a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color='red'>-47.5%</font>) <a href=\"https://seekingalpha.com/pr/16888718-immunocellular-therapeutics-announces-pricing-public-offering-convertible-preferred-stock\" target=\"_blank\">prices </a>its public offering of 5,000 shares of Series B 8% Mandatorily Convertible Preferred Stock and warrants to purchase up to 9,000 shares of Preferred Stock at $1,000 per share and related warrants. Gross proceeds should be ~$5M.</li><li>Each Preferred Share will be sold with 0.6 of Series 1 warrant to purchase one Preferred Share, 0.6 of a Series 2 warrant to purchase one Preferred Share and 0.6 of a Series 3 warrant to purchase one Preferred Share.</li><li>The Preferred Stock has an initial stated value of $1,080 and is convertible into common stock at a conversion price of the lesser of $1.22 or 87.5% of the lowest volume-weighted average price during the 10 days leading up to the conversion date. The floor price is $0.35. Each warrant is exercisable at $1,000 per Preferred Share.</li><li>Closing date is July 21.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279211\" data-linked=\"Immunocellular prices equity offering; shares down 48%\" data-tweet=\"$IMUC - Immunocellular prices equity offering; shares down 48% https://seekingalpha.com/news/3279211-immunocellular-prices-equity-offering-shares-down-48?source=tweet\" data-url=\"https://seekingalpha.com/news/3279211-immunocellular-prices-equity-offering-shares-down-48\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279210\" data-ts=\"1500387603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSGN\" target=\"_blank\">MSGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279210-msg-networksminus-10-on-report-not-drawing-buyers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MSG Networks -10% on report it&#39;s not drawing buyers</a></h4><ul>   <li>MSG Networks (NYSE:<a href='https://seekingalpha.com/symbol/MSGN' title='MSG Networks'>MSGN</a>) is <font color='red'>10.2% lower</font> today after a piece in the <i>New York Post</i> reports it's <a href=\"http://nypost.com/2017/07/18/no-one-wants-to-buy-james-dolans-tv-networks/\" target=\"_blank\">not drawing buyers</a>.</li>    <li>Speculation had owner James Dolan selling the regional sports net and using proceeds to invest more in Madison Square Garden (<a href=\"http://seekingalpha.com/symbol/MSG\" target=\"_blank\">MSG</a> <font color='green'>+0.2%</font>), but \"Nothing is happening.\"</li>    <li>Combining MSG Networks in New York with its existing holding of YES Network would give Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-1.3%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-1.2%</font>) a dominant city presence, but \"Fox Sports Networks doesn't want it,\" a source told the <i>Post.</i></li>    <li>MSGN (the only publicly traded stand-alone RSN) has <font color='green'>risen 42%</font> over the past 12 months and is at a market cap of $1.7B, maybe too dear for buyers to consider swallowing.</li>    <li>If there isn't a buyer, one analyst suggests Dolan might consider recombining MSG with MSG Networks.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255433-msg-networks-plus-7_4-percent-report-looking-sell\" target=\"_blank\">MSG Networks +7.4% on report it's looking to sell</a> (Apr. 04 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/2808016-msg-wraps-split-analysts-like-sports-entertainment-side\" target=\"_blank\">MSG wraps split, and analysts like the sports/entertainment side</a> (Oct. 01 2015)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279210\" data-linked=\"MSG Networks -10% on report it&#39;s not drawing buyers\" data-tweet=\"$MSGN $MSGN $FOX - MSG Networks -10% on report it&#39;s not drawing buyers https://seekingalpha.com/news/3279210-msg-networksminus-10-on-report-not-drawing-buyers?source=tweet\" data-url=\"https://seekingalpha.com/news/3279210-msg-networksminus-10-on-report-not-drawing-buyers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279205\" data-ts=\"1500386506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIX\" target=\"_blank\">SIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279205-six-flagsminus-4_5-duffey-departs-reid-anderson-back-president-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Six Flags -4.5% as Duffey departs; Reid-Anderson back as President/CEO</a></h4><ul>     <li>Six Flags (<a href='https://seekingalpha.com/symbol/SIX' title='Six Flags Entertainment Corporation'>SIX</a> <font color='red'>-4.4%</font>) plunges at the open on news that President and CEO John Duffey has <a href=\"https://seekingalpha.com/pr/16889353-reid-anderson-named-chairman-president-ceo-six-flags\" target=\"_blank\">left the company</a>, effective immediately, to be replaced by Chairman Jim Reid-Anderson.</li><li>Duffey was President and CEO only since February 2016 after joining SIX in 2010 as CFO; no explanation was provided for his departure.</li>     <li>Reid-Anderson was Chairman, President and CEO during 2010-16, and has since been serving as Executive Chairman.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279205\" data-linked=\"Six Flags -4.5% as Duffey departs; Reid-Anderson back as President/CEO\" data-tweet=\"$SIX - Six Flags -4.5% as Duffey departs; Reid-Anderson back as President/CEO https://seekingalpha.com/news/3279205-six-flagsminus-4_5-duffey-departs-reid-anderson-back-president-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3279205-six-flagsminus-4_5-duffey-departs-reid-anderson-back-president-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279201\" data-ts=\"1500386410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGNC\" target=\"_blank\">AGNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279201-mortgage-reit-sector-under-pressure-annaly-raises-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mortgage REIT sector under pressure as Annaly raises capital</a></h4><ul><li>Nearly all of the sector trades above book value, and Annaly Capital last night became the latest to<a href=\"https://seekingalpha.com/news/3279195-annaly-capital-4-percent-share-sale\" target=\"_blank\"> take advantage and sell shares</a>, with a more than $700M offering. It's&nbsp;<font color='red'>down 4.2%</font>.</li><li>The iShares FTSE Nareit mREIT ETF (<a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a> <font color='red'>-1.5%</font>), the Market Vectors ETF Trust (<a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a> <font color='red'>-1.1%</font>), The ETracs 2x Leveraged mREIT ETN (<a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a> <font color='red'>-2.3%</font>)</li><li>Among individual issues (some of which have also recently raised capital): AGNC Investment (<a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color='red'>-1.4%</font>), Armour Residential (<a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a> <font color='red'>-1.5%</font>), Chimera Investment (<a href='https://seekingalpha.com/symbol/CIM' title='Chimera Investment Corporation'>CIM</a> <font color='red'>-1.4%</font>), CYS Investments (<a href='https://seekingalpha.com/symbol/CYS' title='CYS Investments, Inc.'>CYS</a> <font color='red'>-1.2%</font>), Invesco Mortgage (<a href='https://seekingalpha.com/symbol/IVR' title='Invesco Mortgage Capital Inc.'>IVR</a> <font color='red'>-1.5%</font>), Two Harbors (<a href='https://seekingalpha.com/symbol/TWO' title='Two Harbors Investment Corp.'>TWO</a> <font color='red'>-1.6%</font>).</li><li>The 10-year Treasury yield this morning is lower by 3.7 basis points to 2.279%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279201\" data-linked=\"Mortgage REIT sector under pressure as Annaly raises capital\" data-tweet=\"$AGNC $REM $MORT - Mortgage REIT sector under pressure as Annaly raises capital https://seekingalpha.com/news/3279201-mortgage-reit-sector-under-pressure-annaly-raises-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3279201-mortgage-reit-sector-under-pressure-annaly-raises-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279197\" data-ts=\"1500385530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279197-netflixplus-9_3-basking-in-q2-sub-success-analyst-praise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix +9.3%, basking in Q2 sub success, analyst praise</a></h4><ul>   <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) has carried <a href=\"https://seekingalpha.com/news/3279019-netflix-jumps-8_2-percent-revenues-beat-subscriber-count-gets-jolt\" target=\"_blank\">last night's aftermarket gains</a> into the regular session, <font color='green'>up 9.3%</font> after its <a href=\"https://seekingalpha.com/news/3279017-netflix-misses-0_01-beats-revenue\" target=\"_blank\">Q2 results</a> showed better subscriber gains than expected and sub momentum expected to carry into Q3.</li>    <li>Analysts are rolling in with praise for the company's content slate, credited with driving the gains.</li>    <li>BofA Merrill Lynch raised its price target to $199 from $184, implying 23% upside, and analyst Nat Schindler sees a bull case for the <a href=\"https://www.streetinsider.com/Analyst+Comments/Netflix+%28NFLX%29+PT+Raised+to+%24199+at+BofAMerrill+Lynch%2C+Bull+Case+Calls+For+%24300Shr./13104884.html\" target=\"_blank\">stock to hit $300</a>. Pricing is the major driver, he notes, and further price hikes to the faster-growing international business boost that bull case.</li>    <li>Cowen's about that bullish, with a $197 price target (up from $170), and John Blackledge says the company crushed typical seasonality with the sub numbers. Hours of original content were up about 130% Y/Y and should drive similar Q3 results along with stable prices and more integration into set-top boxes.</li>    <li>\"NFLX has an unstoppable lead domestically, clearly has first-mover advantage internationally,\" says Rosenblatt's Alan Gould, who upgraded to Buy and boosted Netflix's price target to $200 from $155. The company's building a moat in content and acts as its own distributor, he notes, making for profitability.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279031-netflix-finance-heavy-content-spending-debt\" target=\"_blank\">Netflix to finance heavy content spending with debt</a> (Jul. 17 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279197\" data-linked=\"Netflix +9.3%, basking in Q2 sub success, analyst praise\" data-tweet=\"$NFLX - Netflix +9.3%, basking in Q2 sub success, analyst praise https://seekingalpha.com/news/3279197-netflixplus-9_3-basking-in-q2-sub-success-analyst-praise?source=tweet\" data-url=\"https://seekingalpha.com/news/3279197-netflixplus-9_3-basking-in-q2-sub-success-analyst-praise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279195\" data-ts=\"1500385469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279195-annaly-capital-down-4-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Annaly Capital down 4% after share sale</a></h4><ul><li>The company sold 60M shares for expected gross proceeds of about $710M, suggesting a sale price in the area of $11.83. The underwriters have an option to buy up to another 9M shares at that price.</li><li><a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a>&nbsp;<font color='red'>-3.9%</font>&nbsp;to $11.78.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16889071-b-annaly-b-capital-management-inc-announces-pricing-public-offering-common-stock\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279052-along-capital-raise-annaly-reports-preliminary-q2-results\" target=\"_blank\">Along with capital raise, Annaly reports preliminary Q2 results</a> (July 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279195\" data-linked=\"Annaly Capital down 4% after share sale\" data-tweet=\"$NLY - Annaly Capital down 4% after share sale https://seekingalpha.com/news/3279195-annaly-capital-down-4-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3279195-annaly-capital-down-4-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279189\" data-ts=\"1500384547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279189-moleculin-in-licenses-leukemia-candidate-from-md-anderson-shares-ahead-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin in-licenses leukemia candidate from MD Anderson; shares ahead 28% premarket</a></h4><ul><li>Nano cap Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) is up&nbsp;<font color='green'>28%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16888842-moleculin-signs-agreement-md-anderson-cancer-center-leukemia-drug-annamycin\" target=\"_blank\">announcement </a>that it has signed a license agreement with MD Anderson Cancer Center for Annamycin for the treatment of relapsed/refractory acute myeloid leukemia &#40;AML&#41;.</li><li>It intends to file new patent applications before advancing into clinical trials.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279189\" data-linked=\"Moleculin in-licenses leukemia candidate from MD Anderson; shares ahead 28% premarket\" data-tweet=\"$MBRX - Moleculin in-licenses leukemia candidate from MD Anderson; shares ahead 28% premarket https://seekingalpha.com/news/3279189-moleculin-in-licenses-leukemia-candidate-from-md-anderson-shares-ahead-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279189-moleculin-in-licenses-leukemia-candidate-from-md-anderson-shares-ahead-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279187\" data-ts=\"1500384330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETH\" target=\"_blank\">ETH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279187-ethan-allenminus-4_8-preliminary-q4-eps-falls-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ethan Allen -4.8% as preliminary Q4 EPS falls short</a></h4><ul>   <li>Ethan Allen Interiors (NYSE:<a href='https://seekingalpha.com/symbol/ETH' title='Ethan Allen Interiors Inc.'>ETH</a>) is <font color='red'>4.8% lower</font> premarket after it notes <a href=\"http://www.nasdaq.com/press-release/ethan-allen-comments-on-business-in-advance-of-investor-meeting-and-announces-earnings-release-dat-20170717-01121\" target=\"_blank\">preliminary earnings figures</a> for its fourth quarter are expected at $0.41-$0.42, short of consensus for $0.50.</li>    <li>Retail written orders took a hit in April, dropping 7.1% before rising 7% in May and 6.9% in June (1.9% Y/Y increase for the quarter).</li>    <li>The company faces \"very tough comparatives\" with last year, and current-year Q4 saw national advertising up 27.5%.</li>    <li>\"While these many initiatives, coupled with a substantial expansion of our advertising, have resulted in increased operating expenses compared to the prior year, they are now substantially completed,\" says CEO Farooq Kathwari. \"We are well positioned for our fiscal 2018 and remain cautiously optimistic.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279187\" data-linked=\"Ethan Allen -4.8% as preliminary Q4 EPS falls short\" data-tweet=\"$ETH - Ethan Allen -4.8% as preliminary Q4 EPS falls short https://seekingalpha.com/news/3279187-ethan-allenminus-4_8-preliminary-q4-eps-falls-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3279187-ethan-allenminus-4_8-preliminary-q4-eps-falls-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279185\" data-ts=\"1500384186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279185-cymabay-readies-10m-share-stock-offering-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay readies 10M-share stock offering, shares down 6% premarket</a></h4><ul><li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a>) slumps&nbsp;<font color='green'>6%</font>&nbsp;premarket on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16888451-cymabay-announces-proposed-public-offering-common-stock\" target=\"_blank\">proposed public offering</a> of 10M shares of common stock. Underwriters over-allotment is an additional 1.5M shares. The price has yet to be released.</li><li>Net proceeds will fund the ongoing development of seladelpar, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279185\" data-linked=\"CymaBay readies 10M-share stock offering, shares down 6% premarket\" data-tweet=\"$CBAY - CymaBay readies 10M-share stock offering, shares down 6% premarket https://seekingalpha.com/news/3279185-cymabay-readies-10m-share-stock-offering-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279185-cymabay-readies-10m-share-stock-offering-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279181\" data-ts=\"1500383870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279181-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color='red'>-52%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16888718-immunocellular-therapeutics-announces-pricing-public-offering-convertible-preferred-stock\" target=\"_blank\">pricing</a> convertible preferred stock and warrants.</li><li><a href='https://seekingalpha.com/symbol/ERIC' title='LM Ericsson Telephone Company'>ERIC</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279084-lm-ericsson-telephone-company-reports-q2-results\" target=\"_blank\">Q2 results</a>.</li><li><a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279117-harley-davidson-lowering-fy2017-shipment-guidance\" target=\"_blank\">lowering</a> FY2017 shipment guidance.</li><li><a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279027-cymabay-readies-1_5m-share-stock-offering-shares-4-percent-hours\" target=\"_blank\">announcing</a> proposed public offering of 1.5M shares of common stock.</li><li><a href='https://seekingalpha.com/symbol/VNOM' title='Viper Energy Partners LP'>VNOM</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279065-viper-energy-partners-launch-11m-unit-offering\" target=\"_blank\">announcing</a> public offering of 11M common units.</li><li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3278985-pareteum-minus-9_4-percent-warrant-exercise-agreement\" target=\"_blank\">warrant</a> exercise agreement.</li><li><a href='https://seekingalpha.com/symbol/REI' title='Ring Energy, Inc.'>REI</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279055-ring-energy-minus-5-percent-news-public-offering\" target=\"_blank\">announcing</a> common stock offering.</li><li>SCSS&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279018-select-comfort-misses-0_07-misses-revenue\" target=\"_blank\">Q2 earnings</a> miss.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3279181\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$IMUC $ERIC $CRDS - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3279181-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3279181-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279180\" data-ts=\"1500383858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279180-hap-study-confirms-value-proposition-of-nektars-euphoria-lite-opioid-candidate-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HAP study confirms the value proposition of Nektar&#39;s euphoria-lite opioid candidate; shares ahead 6% premarket</a></h4><ul><li>Nektar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16888922-nektar-announces-topline-data-human-abuse-potential-study-nktrminus-181-first-class\" target=\"_blank\">announcement </a>of positive results from a Human Abuse Potential &#40;HAP&#41; study of NKTR-181, an opioid analgesic designed to deliver pain relief without the high levels of euphoria of traditional opioids that can lead to abuse and addiction.</li><li>The HAP study compared the degree of drug liking of NKTR-181 to oxycodone in 54 recreational drug users. All three doses of NKTR-181 demonstrated significantly lower peak drug liking scores than oxycodone.</li><li>Complete data will be submitted for presentation at a future medical conference.</li><li>NKTR-181 has Fast Track status in the U.S. for the treatment of moderate-to-severe chronic pain.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279180\" data-linked=\"HAP study confirms the value proposition of Nektar&#39;s euphoria-lite opioid candidate; shares ahead 6% premarket\" data-tweet=\"$NKTR - HAP study confirms the value proposition of Nektar&#39;s euphoria-lite opioid candidate; shares ahead 6% premarket https://seekingalpha.com/news/3279180-hap-study-confirms-value-proposition-of-nektars-euphoria-lite-opioid-candidate-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3279180-hap-study-confirms-value-proposition-of-nektars-euphoria-lite-opioid-candidate-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279178\" data-ts=\"1500383713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279178-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>&nbsp;<font color='green'>+19%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16888842-moleculin-signs-agreement-md-anderson-cancer-center-leukemia-drug-annamycin\" target=\"_blank\">signing</a> a new technology license agreement with MD Anderson Cancer Center based on new patent applications.</li><li><a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>&nbsp;<font color='green'>+9%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3279017-netflix-misses-0_01-beats-revenue\" target=\"_blank\">earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>&nbsp;<font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279160-rite-aid-plus-7-percent-better-expected-post-sale-pro-forma-metrics\" target=\"_blank\">better than expected</a> post-sale pro forma metrics.</li><li><a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>&nbsp;<font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279178\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$MBRX $NFLX $PBYI - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3279178-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3279178-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279177\" data-ts=\"1500383636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEII\" target=\"_blank\">SEII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279177-cleantech-to-evaluate-potential-deals-sharesplus-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleantech to evaluate potential deals; shares +5%</a></h4><ul>     <li>Cleantech Solutions (CLNT)&nbsp;<font color='green'>+5.1%</font> premarket after saying it formed a special committee to explore potential business cooperation, including <a href=\"https://seekingalpha.com/pr/16888712-cleantech-solutions-international-forms-special-committee-retains-financial-advisor-evaluate\" target=\"_blank\">a potential acquisition</a>, by ECrent Capital Holdings.</li>     <li>CLNT already had been in talks with ECrent  on <a href=\"https://seekingalpha.com/news/3273166-cleantech-plus-25-percent-news-potential-takeover-talks\" target=\"_blank\">plans to develop</a> and operate a global rental platform to promote sharing economy across 30 countries and regions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279177\" data-linked=\"Cleantech to evaluate potential deals; shares +5%\" data-tweet=\"$SEII - Cleantech to evaluate potential deals; shares +5% https://seekingalpha.com/news/3279177-cleantech-to-evaluate-potential-deals-sharesplus-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3279177-cleantech-to-evaluate-potential-deals-sharesplus-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279170\" data-ts=\"1500382689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279170-sarepta-and-biomarin-settle-exon-skipping-patent-fight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta and BioMarin settle exon skipping patent fight</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) and BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) <a href=\"https://seekingalpha.com/pr/16889065-sarepta-therapeutics-biomarin-pharmaceutical-inc-announce-execution-global-settlement-license\" target=\"_blank\">settle their patent litigation</a> related to exon skipping.</li><li>Under the terms of the settlement, Sarepta will pay BioMarin $35M and additional regulatory and commercial milestone payments for exons 45, 51 and 53 and potentially on future exon skipping products. It will also pay BioMarin an 8% royalty on EXONDYS 51 sales through 2023 in the EU and other countries where certain BioMarin/AZL patents exist.</li><li>Sarepta will have exclusive rights to BioMarin's DMD patent estate for EXONDYS 51 and all future exon-skipping products. BioMarin retains the right to convert the license to co-exclusive if it decides to develop and commercialize its own exon-skipping therapy for DMD.</li><li>SRPT is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume. BMRN is up a fraction on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3209901-sarepta-prevails-biomarin-patent-fight-exon-skipping-shares-13-percent\" target=\"_blank\">Sarepta prevails over BioMarin in patent fight over exon skipping; shares up 13%</a> (Sept. 20, 2016)</li><li>Previously: <a href=\"https://seekingalpha.com/news/2803436-sarepta-losing-end-exon-51-skipping-patent-ruling-favor-biomarin-plans-appeal\" target=\"_blank\">Sarepta on losing end of exon 51 skipping patent ruling in favor of BioMarin, plans to appeal</a> (Sept. 30, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279170\" data-linked=\"Sarepta and BioMarin settle exon skipping patent fight\" data-tweet=\"$SRPT $SRPT $BMRN - Sarepta and BioMarin settle exon skipping patent fight https://seekingalpha.com/news/3279170-sarepta-and-biomarin-settle-exon-skipping-patent-fight?source=tweet\" data-url=\"https://seekingalpha.com/news/3279170-sarepta-and-biomarin-settle-exon-skipping-patent-fight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279168\" data-ts=\"1500382516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279168-charles-schwab-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charles Schwab EPS in-line, beats on revenue</a></h4><ul><li>Charles Schwab (NYSE:<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>): Q2 EPS of $0.39 in-line.</li><li>Revenue of $2.13B (+16.4% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+2.42%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16889146-schwab-reports-record-quarterly-net-income-575-million-27-percent'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279168\" data-linked=\"Charles Schwab EPS in-line, beats on revenue\" data-tweet=\"$SCHW - Charles Schwab EPS in-line, beats on revenue https://seekingalpha.com/news/3279168-charles-schwab-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279168-charles-schwab-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279166\" data-ts=\"1500382431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLD\" target=\"_blank\">PLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279166-prologis-up-1_25-after-upside-surprise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prologis up 1.25% after upside surprise</a></h4><ul><li>\"Market rent growth surprised us to the upside,\" says Prologis CEO&nbsp;Hamid Moghadam, after his company reported Q2 core FFO per share of $0.84 - up from $0.60 a year ago and topping estimates by $0.06.</li><li>Net effective rent change was 24% vs. 17.8% a year ago. Cash rent change of 11.2% vs. 7.9%.</li><li>Net effective same-store NOI growth of 4.6% vs. 6.1% a year ago. Cash same-store NOI growth of 7.2% vs. 5.3%.</li><li>Full-year core FFO guidance is lifted to $2.78-$2.82 per share from $2.72-$2.78 previously.</li><li><a href=\"http://ir.prologis.com\" target=\"_blank\">Conference call at noon ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279140-prologis-beats-0_06\" target=\"_blank\">Prologis beats by $0.06</a> (July 18)</li><li><a href='https://seekingalpha.com/symbol/PLD' title='Prologis'>PLD</a>&nbsp;<font color='green'>+1.25%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3279166\" data-linked=\"Prologis up 1.25% after upside surprise\" data-tweet=\"$PLD - Prologis up 1.25% after upside surprise https://seekingalpha.com/news/3279166-prologis-up-1_25-after-upside-surprise?source=tweet\" data-url=\"https://seekingalpha.com/news/3279166-prologis-up-1_25-after-upside-surprise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279161\" data-ts=\"1500381774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279161-array-biopharma-up-2-premarket-on-collaboration-amgen-in-autoimmune-disorders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array BioPharma up 2% premarket on collaboration with Amgen in autoimmune disorders</a></h4><ul><li>Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on modest volume in response to the news that it has inked a <a href=\"https://seekingalpha.com/pr/16888939-amgen-array-biopharma-announce-preclinical-license-collaboration-agreement-inflammation\" target=\"_blank\">collaboration agreement</a> with Amgen to discover and develop new drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered via Array's proprietary platform.</li><li>Under the terms of the partnership, the companies will collaborate on preclinical development with Array leading the medicinal chemistry work. Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to the program, Amgen will pay Array upfront and milestone payments and sales-based royalties. Specific financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279161\" data-linked=\"Array BioPharma up 2% premarket on collaboration with Amgen in autoimmune disorders\" data-tweet=\"$ARRY - Array BioPharma up 2% premarket on collaboration with Amgen in autoimmune disorders https://seekingalpha.com/news/3279161-array-biopharma-up-2-premarket-on-collaboration-amgen-in-autoimmune-disorders?source=tweet\" data-url=\"https://seekingalpha.com/news/3279161-array-biopharma-up-2-premarket-on-collaboration-amgen-in-autoimmune-disorders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279160\" data-ts=\"1500381721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279160-rite-aidplus-7-on-better-expected-post-sale-pro-forma-metrics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid +7% on better than expected post-sale pro forma metrics</a></h4><ul>     <li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) <font color='green'>+6.9%</font> premarket after providing <a href=\"https://seekingalpha.com/filing/3627386\" target=\"_blank\">pro forma information</a> on the impact of the proposed sale of stores and assets to Walgreens Boots Alliance on its operations and capital structure.</li>     <li>Despite selling nearly half its stores, RAD says pro forma adjusted EBITDA after the sale for the year ended March 4, 2017 totaled nearly $743M vs. $1.13B before the sale.</li>     <li>RAD also estimates average pro forma total store sales for the year ended March 4 following the sale was $6.1M, vs. $5.7M before the sale.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279160\" data-linked=\"Rite Aid +7% on better than expected post-sale pro forma metrics\" data-tweet=\"$RAD - Rite Aid +7% on better than expected post-sale pro forma metrics https://seekingalpha.com/news/3279160-rite-aidplus-7-on-better-expected-post-sale-pro-forma-metrics?source=tweet\" data-url=\"https://seekingalpha.com/news/3279160-rite-aidplus-7-on-better-expected-post-sale-pro-forma-metrics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>74&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279153\" data-ts=\"1500380577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGS\" target=\"_blank\">MDGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279153-medigus-expands-muse-distribution-deal-in-china-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medigus expands MUSE distribution deal in China; shares ahead 8% premarket</a></h4><ul><li>Thinly traded nano cap Medigus Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a>) perks up&nbsp;<font color='green'>8%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16888774-medigus-golden-grand-expand-distribution-arrangement-china-27m-muse-systems\" target=\"_blank\">announcement </a>that strong interest in its Medigus Ultrasonic Surgical Endostapler &#40;MUSE&#41; in China is the driver behind the expansion of its exclusive distribution agreement with Golden Grand.</li><li>The expanded deal includes a commitment by Golden to buy at least $27M of MUSE systems and related equipment over a period of five years after CFDA approval. The prior deal specified a commitment to buy $17M worth of kit.</li><li>The MUSE system is a single-use transoral stapler that incorporates an ultrasonic sight and range finder and a micro ScoutCam CMOS camera, enabling a single doctor to perform an incisionless transoral fundoplication (a procedure to treat the anatomical cause of gastroesophageal reflux disease or GERD). Since the device does not require any incisions, there is much less discomfort for the patient during the procedure with hospital stays reduced by up to 50%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3260683-muse-procedures-advancing-china-medigus-18-percent-premarket\" target=\"_blank\">MUSE procedures advancing in China; Medigus up 18% premarket</a> (April 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279153\" data-linked=\"Medigus expands MUSE distribution deal in China; shares ahead 8% premarket\" data-tweet=\"$MDGS - Medigus expands MUSE distribution deal in China; shares ahead 8% premarket https://seekingalpha.com/news/3279153-medigus-expands-muse-distribution-deal-in-china-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279153-medigus-expands-muse-distribution-deal-in-china-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279148\" data-ts=\"1500379593\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LMT\" target=\"_blank\">LMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279148-lockheed-martin-moves-toward-record-high-after-q2-beat-guidance-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lockheed Martin moves toward record high after Q2 beat, guidance boost</a></h4><ul>     <li>Lockheed Martin (NYSE:<a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a>) <font color='green'>+0.9%</font> premarket                                                                                                                                                            and poised to open at a record high after reporting better than expected <a href=\"https://seekingalpha.com/news/3279125-lockheed-martin-beats-0_12-beats-revenue\" target=\"_blank\">Q2 earnings</a> and  raising its full-year outlook.</li>     <li>LMT now sees FY 2017 EPS of $12.30-$12.60 from earlier guidance of $12.15-$12.45, vs. $12.51 analyst consensus estimate, and revenues of $49.8B-$51B from $49.5B-$50.7B earlier and $50.2B analyst consensus.</li>     <li>Q2 revenues rose 9.6% Y/Y to $12.69B, also beating expectations, as a 19% rise in net sales in the aeronautics segment and a 9% jump in space systems' net sales offset a 3% decline in the missiles  and fire control business.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279148\" data-linked=\"Lockheed Martin moves toward record high after Q2 beat, guidance boost\" data-tweet=\"$LMT - Lockheed Martin moves toward record high after Q2 beat, guidance boost https://seekingalpha.com/news/3279148-lockheed-martin-moves-toward-record-high-after-q2-beat-guidance-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3279148-lockheed-martin-moves-toward-record-high-after-q2-beat-guidance-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279134\" data-ts=\"1500378726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279134-goldman-tops-trading-revenue-tumbles-40-shares-down-0_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman tops, but trading revenue tumbles 40%; shares down 0.9%</a></h4><ul><li>Investment Banking revenue of $1.73B down 3% Y/Y. Financial advisory revenue of $749M down 6% thanks to lower M&amp;A; underwriting revenue of $981M about flat.</li><li>Institutional Client Services revenue of $3.05B down 17% Y/Y. FICC revenue of $1.16B down 40% - \"a challenging environment characterized by low levels of volatility, low client activity and generally difficult market-making conditions.\"</li><li>Investing &amp; Lending revenue of $1.58B up 42% Y/Y.</li><li>Investment Management revenue of $1.53B up 13% Y/Y.</li><li>Comp and benefits expense of $3.23B down 3% Y/Y; ratio to revenue of 41% vs. 42% a year ago.</li><li>CET 1 ratio of 13.9% down 30 basis points during the quarter. Tangible book value per share of $177.20. 6.6M shares bought back during quarter for $1.47B.</li><li><a href=\"http://www.goldmansachs.com/investor-relations/\" target=\"_blank\">Conference call at 9:30 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279130-goldman-sachs-beats-0_56-beats-revenue\" target=\"_blank\">Goldman Sachs beats by $0.56, beats on revenue</a> (July 18)</li><li><a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>&nbsp;<font color='red'>-0.9%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3279134\" data-linked=\"Goldman tops, but trading revenue tumbles 40%; shares down 0.9%\" data-tweet=\"$GS - Goldman tops, but trading revenue tumbles 40%; shares down 0.9% https://seekingalpha.com/news/3279134-goldman-tops-trading-revenue-tumbles-40-shares-down-0_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3279134-goldman-tops-trading-revenue-tumbles-40-shares-down-0_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279132\" data-ts=\"1500378605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVAX\" target=\"_blank\">NVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279132-novavax-to-host-rsv-f-vaccine-update-july-24-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novavax to host RSV F vaccine update July 24; shares ahead 8% premarket</a></h4><ul><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16888504-novavax-host-rsv-f-vaccine-update-conference-call-webcast-july-24-2017-4-30-pm\" target=\"_blank\">announcement </a>that, on July 24, it will release top-line data from its Phase 2 clinical trial assessing its RSV F Vaccine in older adults, additional data from its prior Phase 2 and Phase 3 studies in older adults and data from its Phase 3 study in infants via maternal immunization. The conference call will begin at 4:30 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279132\" data-linked=\"Novavax to host RSV F vaccine update July 24; shares ahead 8% premarket\" data-tweet=\"$NVAX - Novavax to host RSV F vaccine update July 24; shares ahead 8% premarket https://seekingalpha.com/news/3279132-novavax-to-host-rsv-f-vaccine-update-july-24-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279132-novavax-to-host-rsv-f-vaccine-update-july-24-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279131\" data-ts=\"1500378330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279131-rio-tinto-cuts-2017-iron-ore-guidance-after-q2-cargoes-slide-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto cuts 2017 iron ore guidance after Q2 cargoes slide 6%</a></h4><ul>     <li>Rio Tinto (NYSE:<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a>) <font color='red'>-1.8%</font> premarket after <a href=\"http://www.reuters.com/article/us-usa-immigration-visas-idUSKBN1A21PA\" target=\"_blank\">cutting its forecast for 2017 shipments of iron ore</a> by as much as 10M metric tons, after poor weather and an acceleration of its rail maintenance program hurt Q2 shipments.</li>     <li>Rio now expects shipments from Australia of ~330M metric tons for the full year, at the low end of its April guidance of 330M-340M tons.</li>     <li><a href=\"http://www.riotinto.com/documents/170718_Rio_Tinto_releases_second_quarter_production_results.pdf\" target=\"_blank\">Q2 Pilbara iron ore shipments</a> totaled 77.7M metric tons, down 6% Y/Y and slightly below analyst expectations, while iron ore production was 79.8M tons, 1% lower than last year.</li>     <li>Rio delivered record quarterly bauxite production of 12.9M tons in Q2, up 7% Y/Y; copper production fell 6% Y/Y due to the strike at the Escondida mine in Chile.</li>     <li>\"To meet guidance newly issued production guidance RIO will have to run hard in 2H17, as their annualized 1H run rate is only 93% of iron ore guidance, 83% of copper guidance and 87% of coking coal guidance,\"&nbsp;Goldman Sachs <a href=\"http://www.barrons.com/articles/rio-tinto-soft-2q-production-iron-ore-seen-at-low-end-of-guidance-analyst-reaction-1500342057\" target=\"_blank\">says</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279131\" data-linked=\"Rio Tinto cuts 2017 iron ore guidance after Q2 cargoes slide 6%\" data-tweet=\"$RIO - Rio Tinto cuts 2017 iron ore guidance after Q2 cargoes slide 6% https://seekingalpha.com/news/3279131-rio-tinto-cuts-2017-iron-ore-guidance-after-q2-cargoes-slide-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3279131-rio-tinto-cuts-2017-iron-ore-guidance-after-q2-cargoes-slide-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279129\" data-ts=\"1500378035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279129-pound-lower-after-soft-u-k-inflation-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pound lower after soft U.K. inflation data</a></h4><ul><li><a href=\"https://www.ft.com/content/35893f0b-1302-33ed-8c1d-90472bd1e04d?mhq5j=e2\" target=\"_blank\">Annual inflation fell to 2.6%</a> in June, well short of expectations for the rate to be unchanged at 2.9%.</li><li>Calling the print \"a real surprise,\" Aberdeen Asset's Lucy O'Carroll says it's \"going to kill the chances\" a of rate hike anytime soon.</li><li>The pound (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXB' title='CurrencyShares British Pound Sterling Trust ETF'>FXB</a>) tumbled earlier this morning on the news, and hasn't really recovered, now&nbsp;<font color='red'>down 0.3%</font>&nbsp;vs. the dollar to $1.3019. The FTSE is flat on the session, with the rest of Europe in the red.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXB' title='CurrencyShares British Pound Sterling Trust ETF'>FXB</a>, <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/GBB' title='iPath GBP/USD Exchange Rate ETN'>GBB</a>, <a href='https://seekingalpha.com/symbol/DBUK' title='Deutsche X-trackers MSCI United Kingdom Hedged Equity ETF'>DBUK</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/EWUS' title='iShares MSCI United Kingdom Small Cap Index ETF'>EWUS</a>, <a href='https://seekingalpha.com/symbol/DXPS' title='WisdomTree United Kingdom Hedged Equity ETF'>DXPS</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a>, <a href='https://seekingalpha.com/symbol/QGBR' title='SPDR MSCI United Kingdom Quality Mix ETF'>QGBR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279129\" data-linked=\"Pound lower after soft U.K. inflation data\" data-tweet=\"$FXB $EWU $GBB - Pound lower after soft U.K. inflation data https://seekingalpha.com/news/3279129-pound-lower-after-soft-u-k-inflation-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3279129-pound-lower-after-soft-u-k-inflation-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279125\" data-ts=\"1500377564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LMT\" target=\"_blank\">LMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279125-lockheed-martin-beats-0_12-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lockheed Martin beats by $0.12, beats on revenue</a></h4><ul><li>Lockheed Martin (NYSE:<a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a>): Q2 EPS of $3.23 <font color='green'>beats by $0.12</font>.</li><li>Revenue of $12.69B (+9.6% Y/Y) <font color='green'>beats by $270M</font>.</li><li>Shares <font color='green'>+2.6%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16888848-lockheed-martin-reports-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279125\" data-linked=\"Lockheed Martin beats by $0.12, beats on revenue\" data-tweet=\"$LMT - Lockheed Martin beats by $0.12, beats on revenue https://seekingalpha.com/news/3279125-lockheed-martin-beats-0_12-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279125-lockheed-martin-beats-0_12-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279122\" data-ts=\"1500376952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279122-novartis-q2-sales-down-2-non-gaap-eps-down-1-shares-ahead-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis Q2 sales down 2%; non-GAAP EPS down 1%; shares ahead 3% premarket</a></h4><ul><li>Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) <a href=\"http://hugin.info/134323/R/2120951/808094.pdf\" target=\"_blank\">Q2 results</a>: Revenues: $12,242M (-1.8%); Innovative Medicines: $8,275M (-1.3%); Sandoz: $2,451M (-4.9%); Alcon: $1,516M (+0.7%).</li><li>Oncology: $3,074M (-7.4%); Ophthalmology: $1,378M (-1.9%); &nbsp;Immunology and Dermatology: $979M (+33.4%); Neuroscience: $864M (+2.6%); Respiratory: $393M (-1.0%); Cardio-Metabolic: $113M (+222.9%); Established Medicines: $1,474M (-11.0%); Pharmaceuticals business unit: $5,201M (+2.6%).</li><li>Operating Income: $2,280M (+8.9%); Net Income: $1,979M (+9.6%); EPS: $0.84 (+10.5%); Non-GAAP EPS: $1.22 (-0.8%); Quick Assets: $8,437M (+8.5%); CF Ops: $3,582M (+15.1%).</li><li>Key Growh Drivers: Cosentyx: $490M (+88.5%); Entresto: $110M (+243.8%); Promacta/Revolade: $210M (+32.9%); Tafinlar + Mekinist: $216M (+25.6%); Jakavi: $186M (+27.4%); Tasigna: $463M (+1.1%); Gilenya: $837M (+3.2%); Kisqali: $8M.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279122\" data-linked=\"Novartis Q2 sales down 2%; non-GAAP EPS down 1%; shares ahead 3% premarket\" data-tweet=\"$NVS - Novartis Q2 sales down 2%; non-GAAP EPS down 1%; shares ahead 3% premarket https://seekingalpha.com/news/3279122-novartis-q2-sales-down-2-non-gaap-eps-down-1-shares-ahead-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279122-novartis-q2-sales-down-2-non-gaap-eps-down-1-shares-ahead-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279119\" data-ts=\"1500376729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279119-bofa-dips-1-following-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA dips more than 1% following earnings beat</a></h4><ul><li>Consumer Banking net income of $2.032B vs. $1.674B a year ago, with revenue of $8.5B vs. $7.795B. Net interest income of $5.96B vs/ $5.781B. Noninterest income of $2.548B vs. $2.588B. Noninterest expense of $4.409B vs. $4.418B. Branches down to 4,4542 from 4,681. Mobile banking active users of 22.9M vs. 20.2B. Provisions of $834M vs. $726M.</li><li>Wealth Management net income of $804M vs. $705M a year ago.</li><li>Global Banking net income of $1.786B vs. $1.498B a year ago. Provisions dropped to $15M from $199M thanks mostly to energy.</li><li>Global Markets net income of $928M vs. $1.215B a year ago. Trading revenue fell 9% to $3.4B from $3.7B - FICC revenue fell 14% and equities revenue grew 3%.</li><li>Overall bank provisions fell to $726M from $976M, with net charge-off ratio dropping to 0.40% from 0.44%. Net interest margin dipped five basis points from Q1 to 2.34% - curious, given the bank's supposed leverage to higher interest rates.</li><li>CET1 ratio of 11.6% up from 10.6%. Tangible book value per share of $17.78 vs. $16.71.</li><li><a href=\"http://investor.bankofamerica.com/phoenix.zhtml?c=71595&amp;p=irol-irhome#fbid=0o3lzBIRBou\" target=\"_blank\">Conference call at 8:30 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279113-bank-america-beats-0_03-beats-revenue\" target=\"_blank\">Bank of America beats by $0.03, beats on revenue</a> (July 18)</li><li><a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>&nbsp;<font color='red'>-1.4%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3279119\" data-linked=\"BofA dips more than 1% following earnings beat\" data-tweet=\"$BAC - BofA dips more than 1% following earnings beat https://seekingalpha.com/news/3279119-bofa-dips-1-following-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3279119-bofa-dips-1-following-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279117\" data-ts=\"1500376368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOG\" target=\"_blank\">HOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279117-harley-davidson-down-on-lowering-fy2017-shipment-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harley-Davidson down on lowering FY2017 shipment guidance</a></h4><ul>     <li>Harley-Davidson (NYSE:<a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a>) reports motorcycle revenue decreased 4.5% to $1.27B in Q2.</li>     <li>Parts &amp; accessories revenue slipped 8% to $237.5M.</li>     <li>Motorcycle shipments fell 7.2% to 81,807 units.</li>     <li>Gross margin rate +10 bps to 36.5%.</li>     <li>Operating margin increased 100 bps to 20.3% as a result of mix favorability driven by demand for the Milwaukee-Eight powered touring motorcycles and lower SG&amp;A spending.Financial services revenue declined 1.5% to $188.03M.</li>     <li><b>FY2017 Guidance</b>: Motorcycle shipments: 241K to 246K (-6% to -8% Y/Y); Operating margin rate: ~-1%; Tax rate: ~34.5%; Capex: $200M to $220M.</li>     <li>HOG&nbsp;<font color='red'>-8.08%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279117\" data-linked=\"Harley-Davidson down on lowering FY2017 shipment guidance\" data-tweet=\"$HOG - Harley-Davidson down on lowering FY2017 shipment guidance https://seekingalpha.com/news/3279117-harley-davidson-down-on-lowering-fy2017-shipment-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3279117-harley-davidson-down-on-lowering-fy2017-shipment-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279116\" data-ts=\"1500375839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279116-johnson-johnson-q2-top-line-up-2-earning-off-4-non-gaap-eps-up-5-guidance-raised-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Johnson &amp; Johnson Q2 top line up 2%; earning off 4%; non-GAAP EPS up 5%; guidance raised; shares ahead 2% premarket</a></h4><ul><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) <a href=\"https://seekingalpha.com/pr/16888742-johnson-and-johnson-reports-2017-second-quarter-results\" target=\"_blank\">Q2 results </a>($M): Total Revenues: 18,839 (+1.9%); Consumer: 3,478 (+1.7%); Pharmaceutical: 8,635 (-0.2%); Medical Devices: 6,726 (+4.9%).</li><li>Net Income: 3,827 (-4.3%); non-GAAP EPS: 5,017 (+3.1%); 1.40 (-2.1%); non-GAAP EPS: 1.83 (+5.2%).</li><li>Company says sales growth will accelerate in H2. Global results negatively impacted by baby care products, but partially offset by domestic OTC products.</li><li><strong>2017 Guidance</strong>: Revenues: $75.8B - 76.1B from $75.4B - 76.1B; Non-GAAP EPS: $7.12 - 7.22 from $7.00 - 7.15.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279116\" data-linked=\"Johnson &amp; Johnson Q2 top line up 2%; earning off 4%; non-GAAP EPS up 5%; guidance raised; shares ahead 2% premarket\" data-tweet=\"$JNJ - Johnson &amp; Johnson Q2 top line up 2%; earning off 4%; non-GAAP EPS up 5%; guidance raised; shares ahead 2% premarket https://seekingalpha.com/news/3279116-johnson-johnson-q2-top-line-up-2-earning-off-4-non-gaap-eps-up-5-guidance-raised-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3279116-johnson-johnson-q2-top-line-up-2-earning-off-4-non-gaap-eps-up-5-guidance-raised-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279109\" data-ts=\"1500374527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279109-johnson-and-amp-johnson-beats-0_03-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Johnson &amp;amp; Johnson beats by $0.03, misses on revenue</a></h4><ul><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>): Q2 EPS of $1.83 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $18.84B (+1.9% Y/Y) <font color='red'>misses by $110M</font>.</li><li>Shares <font color='green'>+1.01%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16888742-johnson-and-johnson-reports-2017-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279109\" data-linked=\"Johnson &amp;amp; Johnson beats by $0.03, misses on revenue\" data-tweet=\"$JNJ - Johnson &amp; Johnson beats by $0.03, misses on revenue https://seekingalpha.com/news/3279109-johnson-and-amp-johnson-beats-0_03-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279109-johnson-and-amp-johnson-beats-0_03-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279094\" data-ts=\"1500371781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279094-unitedhealth-group-beats-0_08-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealth Group beats by $0.08,  revenue in-line</a></h4><ul><li>UnitedHealth Group (NYSE:<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a>): Q2 EPS of $2.46 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $50.05B (+7.7% Y/Y) in-line.</li><li>Shares <font color='green'>+1.89%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16888704-unitedhealth-group-second-quarter-highlights'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279094\" data-linked=\"UnitedHealth Group beats by $0.08,  revenue in-line\" data-tweet=\"$UNH - UnitedHealth Group beats by $0.08, revenue in-line https://seekingalpha.com/news/3279094-unitedhealth-group-beats-0_08-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3279094-unitedhealth-group-beats-0_08-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279090\" data-ts=\"1500370959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279090-novartis-beats-0_04-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis beats by $0.04, misses on revenue</a></h4><ul><li>Novartis (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>): Q2 EPS of $1.22 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $12.24B (-1.8% Y/Y) <font color='red'>misses by $30M</font>.</li><li>Shares <font color='green'>+2.67%</font> PM.</li><li><a href='https://www.novartis.com/news/media-releases/q2-results-confirm-full-year-guidance-strong-pipeline-results-underpin-potential'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279090\" data-linked=\"Novartis beats by $0.04, misses on revenue\" data-tweet=\"$NVS - Novartis beats by $0.04, misses on revenue https://seekingalpha.com/news/3279090-novartis-beats-0_04-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279090-novartis-beats-0_04-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279079\" data-ts=\"1500366162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSYY\" target=\"_blank\">TOSYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279079-toshiba-soars-20-after-court-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toshiba soars 20% after court delay</a></h4><ul><li>Toshiba (<a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) shares <font color='green'>jumped almost 20%</font> in Tokyo overnight as investors <a href=\"https://www.nytimes.com/reuters/2017/07/17/business/17reuters-toshiba-accounting.html\" target=\"_blank\">returned</a> from a public holiday on Monday.</li><li>The rally comes after a California court postponed a hearing on Western Digital's (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) attempt to block Toshiba's memory chip business sale.</li><li>Another boost? David Einhorn's Greenlight Capital just revealed a stake in the struggling conglomerate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279079\" data-linked=\"Toshiba soars 20% after court delay\" data-tweet=\"$TOSYY $TOSYY $WDC - Toshiba soars 20% after court delay https://seekingalpha.com/news/3279079-toshiba-soars-20-after-court-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3279079-toshiba-soars-20-after-court-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":71,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}